This transcript highlights the strategic design and successful implementation of Roche's KAPA HyperExome technology and the KAPA HyperExome Edge instrument for whole exome sequencing (WES). It details how capture oligos are balanced and designed to cover disease-relevant exonic and intronic regions by integrating data from comprehensive databases, resulting in high on-target rates and cost-efficient sequencing. The HyperExome Edge instrument is lauded for its user-friendliness, cartridge-based automation, and built-in error prevention. The speaker also demonstrates how HyperExome facilitates the creation of virtual panels and robust copy number variant (CNV) detection, even for single-exon deletions, ultimately leading to a streamlined, single-workflow approach in their laboratory.
Roche KAPA HyperExome: Advancing Whole Exome Sequencing in the Lab
0:00 Optimized Capture Oligo Design: Emphasizes the critical need for balanced capture oligos when combining many target regions, specifically focusing on covering exons and disease-relevant intronic regions.
0:31 Comprehensive Database Integration: Roche uses data from established databases (e.g., HDM, Refac, Clinvar) to ensure capture oligos include known pathogenic variants, even intronic ones, for thorough exome analysis.
1:16 High On-Target Efficiency: The HyperExome product achieves a typical on-target rate of over 80% to exonic sequences, which significantly reduces sequencing costs by minimizing off-target reads.
1:29 KAPA HyperExome Edge Instrument: Introduction of Roche's new, highly user-friendly KAPA HyperExome Edge instrument, which features color-coded and barcoded cartridges for reagents, automated loading verification, and a pre-run scanner to prevent errors.
2:05 Future Automation Goals: The lab aims to replace current Hamilton robots with more integrated systems like the HyperExome Edge to achieve on-deck quantification, further automating their workflow.
2:36 Efficient Manual Hybridization: The lab successfully performs 20-plex hybridizations manually, even exceeding Roche's recommendations, highlighting the approach's effectiveness and manageability.
2:57 Transition to Virtual Panels: The lab has completely shifted its NGS workflow from using traditional gene panels to leveraging the HyperExome as a backbone for creating flexible virtual panels, capitalizing on its even coverage.
3:12 Sensitive CNV Detection Capabilities: The even distribution of coverage allows for reliable copy number variant (CNV) detection, exemplified by the successful identification of a single-exon heterozygous deletion, confirmed by MLPA.
4:09 Streamlined Lab Workflow: Exome analysis has replaced previous panel and single-gene analyses, enabling a single, unified workflow for all genetic analyses within the laboratory.